PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating) traded down 0.7% during mid-day trading on Wednesday . The stock traded as low as $2.93 and last traded at $2.96. 33,345 shares traded hands during mid-day trading, an increase of 278% from the average session volume of 8,831 shares. The stock had previously closed at $2.98.
PharmaCyte Biotech Stock Performance
The company's 50 day moving average price is $2.93 and its 200-day moving average price is $2.90.
About PharmaCyte Biotech
(Get Rating)
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Featured Articles
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.